EMBO Molecular Medicine (Apr 2024)

Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer

  • Alice Gambelli,
  • Anna Nespolo,
  • Gian Luca Rampioni Vinciguerra,
  • Eliana Pivetta,
  • Ilenia Pellarin,
  • Milena S Nicoloso,
  • Chiara Scapin,
  • Linda Stefenatti,
  • Ilenia Segatto,
  • Andrea Favero,
  • Sara D’Andrea,
  • Maria Teresa Mucignat,
  • Michele Bartoletti,
  • Emilio Lucia,
  • Monica Schiappacassi,
  • Paola Spessotto,
  • Vincenzo Canzonieri,
  • Giorgio Giorda,
  • Fabio Puglisi,
  • Andrea Vecchione,
  • Barbara Belletti,
  • Maura Sonego,
  • Gustavo Baldassarre

DOI
https://doi.org/10.1038/s44321-024-00069-3
Journal volume & issue
Vol. 16, no. 5
pp. 1162 – 1192

Abstract

Read online

Abstract Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known about how the acquisition of PT-resistance mediates the increased spreading capabilities of EOC. Here, using isogenic PT-resistant cells, genetic and pharmacological approaches, and patient-derived models, we report that Integrin α6 (ITGA6) is overexpressed by PT-resistant cells and is necessary to sustain EOC metastatic ability and adhesion-dependent PT-resistance. Using in vitro approaches, we showed that PT induces a positive loop that, by stimulating ITGA6 transcription and secretion, contributes to the formation of a pre-metastatic niche enabling EOC cells to disseminate. At molecular level, ITGA6 engagement regulates the production and availability of insulin-like growth factors (IGFs), over-stimulating the IGF1R pathway and upregulating Snail expression. In vitro data were recapitulated using in vivo models in which the targeting of ITGA6 prevents PT-resistant EOC dissemination and improves PT-activity, supporting ITGA6 as a promising druggable target for EOC patients.

Keywords